Your session is about to expire
← Back to Search
Peer Mentoring for HIV/AIDS
N/A
Waitlist Available
Led By Jordan Lake, M.D., M.Sc.
Research Sponsored by Jury Candelario
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6-months post-baseline
Awards & highlights
Study Summary
This study aims to investigate the effectiveness of an in-person peer mentoring and health literacy intervention on improving medication adherence, HIV-1 viral load, CD4+ T lymphocyte counts, and HIV medical appointment attendance among newly-diagnosed and/or medication non-adherent HIV-positive individuals, compared to standard of care provider/staff-delivered education.
Eligible Conditions
- HIV/AIDS
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6-months post-baseline
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6-months post-baseline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Efficacy of Peer Mentoring on Improving Medication Adherence
Secondary outcome measures
Assess the Long-Term Impact of Peer Mentoring on Medication adherence
Other outcome measures
Examine the Impact of Peer Mentoring on HIV Medical Appointment Attendance
Examine the Impact of Peer Mentoring on HIV viral load and CD4 lymphocyte cell counts
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Peer MentoringExperimental Treatment1 Intervention
Between baseline and 4-month follow-up, experiment group patients will be receiving (a) Weekly contacts with their Peer Mentor, with the option of receiving more frequent contact, if needed; and (b) 4 monthly, 1-hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness. In addition, experiment group participants will also be provided with all standard practice services given to control group participants, including: (c) Two more or HIV basics education and medication adherence counseling sessions with their HIV specialty care provider and Patient Navigator; (d) resource referrals from a Patient Navigator based on the participant's needs; and (e) automated medical appointment reminders via phone.
Group II: Standard of CareActive Control1 Intervention
Between baseline and 4-month follow-up, control group patients will receive current standard of care which includes: (a) two or more HIV basics education and medication adherence counseling sessions with their HIV specialty care provider and Patient Navigator; (b) resource referrals from a Patient Navigator based on the participant's needs (e.g., mental health, substance abuse, social support groups, etc.); and (c) automated medical appointment reminders via phone.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Peer Mentoring
2017
N/A
~1070
Find a Location
Who is running the clinical trial?
Jury CandelarioLead Sponsor
Merck Sharp & Dohme LLCIndustry Sponsor
3,899 Previous Clinical Trials
5,062,826 Total Patients Enrolled
Jordan Lake, M.D., M.Sc.Principal InvestigatorApait Health Center
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger